Menu Search
Equities

Voyager Therapeutics Inc

VT6:DEU

Voyager Therapeutics Inc

Actions
  • Price (EUR)6.38
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+8.05%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Voyager Therapeutics Inc grew revenues 511.16% from 40.91m to 250.01m while net income improved from a loss of 46.41m to a gain of 132.33m.
Gross margin--
Net profit margin6.28%
Operating margin-4.63%
Return on assets2.40%
Return on equity3.38%
Return on investment2.71%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Voyager Therapeutics Inc fell by 30.08m. However, the company earned 77.92m from its operations for a Cash Flow Margin of 31.17%. In addition the company generated 33.65m cash from financing while 141.64m was spent on investing.
Cash flow per share0.2657
Price/Cash flow per share26.81
Book value per share6.16
Tangible book value per share6.16
More ▼

Balance sheet in USDView more

Voyager Therapeutics Inc uses little or no debt in its capital structure.
Current ratio9.51
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.